These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 27437883)

  • 1. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
    McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
    JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
    Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
    Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
    Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS
    Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
    Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
    Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    McGuire DK; Alexander JH; Johansen OE; Perkovic V; Rosenstock J; Cooper ME; Wanner C; Kahn SE; Toto RD; Zinman B; Baanstra D; Pfarr E; Schnaidt S; Meinicke T; George JT; von Eynatten M; Marx N;
    Circulation; 2019 Jan; 139(3):351-361. PubMed ID: 30586723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
    Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
    Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
    Scheen AJ; Paquot N
    Rev Med Liege; 2015 Oct; 70(10):511-6. PubMed ID: 26727841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial.
    Cosentino F; Cannon CP; Cherney DZI; Masiukiewicz U; Pratley R; Dagogo-Jack S; Frederich R; Charbonnel B; Mancuso J; Shih WJ; Terra SG; Cater NB; Gantz I; McGuire DK;
    Circulation; 2020 Dec; 142(23):2205-2215. PubMed ID: 33026243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
    Standl E; Stevens SR; Armstrong PW; Buse JB; Chan JCN; Green JB; Lachin JM; Scheen A; Travert F; Van de Werf F; Peterson ED; Holman RR;
    Diabetes Care; 2018 Mar; 41(3):596-603. PubMed ID: 29311155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
    McGuire DK; Shih WJ; Cosentino F; Charbonnel B; Cherney DZI; Dagogo-Jack S; Pratley R; Greenberg M; Wang S; Huyck S; Gantz I; Terra SG; Masiukiewicz U; Cannon CP
    JAMA Cardiol; 2021 Feb; 6(2):148-158. PubMed ID: 33031522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
    Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
    Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic Safety of Sitagliptin in the TECOS Study.
    Buse JB; Bethel MA; Green JB; Stevens SR; Lokhnygina Y; Aschner P; Grado CR; Tankova T; Wainstein J; Josse R; Lachin JM; Engel SS; Patel K; Peterson ED; Holman RR;
    Diabetes Care; 2017 Feb; 40(2):164-170. PubMed ID: 27630212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.
    Toh S; Hampp C; Reichman ME; Graham DJ; Balakrishnan S; Pucino F; Hamilton J; Lendle S; Iyer A; Rucker M; Pimentel M; Nathwani N; Griffin MR; Brown NJ; Fireman BH
    Ann Intern Med; 2016 Jun; 164(11):705-14. PubMed ID: 27110660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
    Green JB; Bethel MA; Armstrong PW; Buse JB; Engel SS; Garg J; Josse R; Kaufman KD; Koglin J; Korn S; Lachin JM; McGuire DK; Pencina MJ; Standl E; Stein PP; Suryawanshi S; Van de Werf F; Peterson ED; Holman RR;
    N Engl J Med; 2015 Jul; 373(3):232-42. PubMed ID: 26052984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials.
    Sacre JW; Magliano DJ; Shaw JE
    Diabetes Care; 2020 Oct; 43(10):2614-2623. PubMed ID: 32958618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sitagliptin and risk of heart failure hospitalization in patients with type 2 diabetes on dialysis: A population-based cohort study.
    Hung YC; Lin CC; Huang WL; Chang MP; Chen CC
    Sci Rep; 2016 Jul; 6():30499. PubMed ID: 27460913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
    Gantz I; Chen M; Suryawanshi S; Ntabadde C; Shah S; O'Neill EA; Engel SS; Kaufman KD; Lai E
    Cardiovasc Diabetol; 2017 Sep; 16(1):112. PubMed ID: 28893244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.